Cushings Syndrome Market Forecasts 2018 - Market Trends, Size, Demand, Cost, Opportunity Analysis and Forecasts to 2018

Market Research Store
Cushings Syndrome Market
Size, Share, Global Trends,
Analysis, Research Report
and Forecast,
2014-2019
www.marketresearchstore.com
sales@marketresearchstore.com

Table of content
Report Description
Market Research Store estimates that the 2013 sales for the Cushing's syndrome
(CS) therapeutic market was approximately $179m across the 6MM covered in
this report. Pharmaceutical and biotechnology companies that are investing their
attention, time, and financial resources in the CS field, have adopted a myriad of
research and development (R&D) strategies. One notable example is the fact that
drug developers are focused on developing superior, next-generation inhibitors of
cortisol synthesis in the adrenal glands. Steroidogenesis inhibitors were
responsible for approximately 28% of total drug sales in the 6MM in 2013,
equating to around $50m. As a consequence of this trend, GlobalData expects
overall revenues generated by this drug class to increase by approximately 390%
to reach around $247m, encompassing 49% of total drug sales in the 6MM in
2018.

Table of content
Report Description
The expansion in this segment of the CS market is fuelled by the introduction of
premium-priced pharmacological agents such as Novartis' LCI699 and Cortendo
AB's NormoCort (COR-003) in the US, as well as the arrival of HRA Pharma's
Ketoconazole HRA (ketoconazole) to the European CS stage. One of the greatest
unmet needs in this indication is a lack of effective drugs directed against the
underlying cause of Cushing's disease (the pituitary tumor). Despite this demand,
pharmaceutical companies are continuing to adopt a strategy that simply targets
the adrenal glands. As a result, there is a vast amount of room for new or existing
players to penetrate the market and capture considerable patient share.
Visit Complete Report @
http://www.marketresearchstore.com/report/opportunityanalyzer-cushingssyndrome-opportunity-analysis-and-forecasts-12416
Request For Sample @
http://www.marketresearchstore.com/report/opportunityanalyzer-cushingssyndrome-opportunity-analysis-and-forecasts-12416#requestSample

Table of content
Report Description
Highlights
Key Questions Answered
Although the current standard of care (ketoconazole) is cheap and reasonably
effective in most CS patients, it possesses worrying safety profiles, inconvenient
dosing schedules, is difficult to obtain and can display waning efficacy over time.
Newer medical treatments, for example, Novartis' Signifor (pasireotide) and
Corcept Therapeutics' Korlym (mifepristone) address only some of these issues;
yet, present their own limitations. The CS market is still marked by the existence
of a multitude of unmet needs. What are the main unmet needs in this market?
Will the drugs under development fulfil the unmet needs of the CS market?
The late-stage CS pipeline is sparsely populated; however, those drugs in
development will be a strong driver of CS market growth. Which of these drugs
will attain high sales revenues during 2013-2018? Which of these drugs will have
the highest peak sales at the highest CAGR, and why?

Table of content
Report Description
Key Findings
One of the main drivers influencing growth in the Cushing's syndrome market will
be the introduction of second-generation steroidogenesis inhibitors, LCI699 and
NormoCort (COR-003), in the US, which will rival existing standard of care medical
treatments.
Another strong driver will be the arrival of Corcept Therapeutics' Korlym
(mifepristone) and HRA Pharma's Ketoconazole HRA (ketoconazole) to the
European CS market. Both drugs will stimulate significant growth here.
The launch of Novartis' Signifor LAR (pasireotide) in the 6MM will equip physicians
with a less frequently administered formulation of Signifor.
Reasons for inadequate CS treatment include poor physician awareness of the
condition, delayed diagnosis, a lack of efficacious drugs for individuals suffering
from severe hypersecretion, and a shortage of effective medicines targeting the
source of Cushing's disease.
Browse Full Report with TOC @
http://www.marketresearchstore.com/report/opportunityanalyzer-cushingssyndrome-opportunity-analysis-and-forecasts-12416#reportTableOfContent

Table of content
Report Description
Scope
Overview of Cushing's syndrome, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized Cushing's syndrome therapeutics market revenues, annual
cost of therapies and treatment usage pattern data from 2013 and forecast for
five years to 2018. Key topics covered include strategic competitor assessment,
market characterization, unmet needs, clinical trial mapping and implications for
the Cushing's syndrome therapeutics market.
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of late-stage
pipeline drugs. Analysis of the current and future market competition in the global
Cushing's syndrome therapeutics market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is independently researched to
provide qualitative analysis of its implications.
Request For Sample @
http://www.marketresearchstore.com/report/opportunityanalyzer-cushingssyndrome-opportunity-analysis-and-forecasts-12416#requestSample

Table of content
Report Description
Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a review
of pipeline products and technologies, and by identifying the companies with the
most robust pipeline. Additionally a list of acquisition targets included in the
pipeline product company list. Develop business strategies by understanding the
trends shaping and driving the Cushing's syndrome therapeutics market.
Drive revenues by understanding the key trends, innovative products and
technologies, market segments, and companies likely to impact the Cushing's
syndrome therapeutics market in the future. Formulate effective sales and
marketing strategies by understanding the competitive landscape and by
analysing the performance of various competitors. Identify emerging players with
potentially strong product portfolios and create effective counter-strategies to
gain a competitive advantage. Track drug sales in the 6MM Cushing's syndrome
therapeutics market from 2013-2018.
Organize your sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments
and strategic partnerships.

About Us
Market Research Store is a single destination for all the industry,
company and country reports. We feature large repository of latest
industry reports, leading and niche company profiles, and market
statistics released by reputed private publishers and public
organizations.
Contact Us
Stay With Us:
TELEPHONE: +1-386-310-3803
E-MAIL:
sales@marketresearchstore.com
Suite #8138, 3422 SW
15 Street,
Deerfield Beach, Florida
33442
United States